`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`TEVA PHARMACEUTICALS USA, INC.,
`Petitioner
`
`V.
`
`CORCEPT THERAPEUTICS, INC.,
`Patent Owner
`
`Case PGR2019-00048
`U.S. Patent No. 10,195,214
`
`DECLARATION OF NICHOLAS A. LOCASTRO
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2048, Page 1
`
`
`
`I, Nicholas A. LoCastro, declare as follows:
`
`1.
`
`I am over the age of eighteen (18) and competent to make this
`
`declaration.
`
`2.
`
`I have personal knowledge of the matters set forth below, and the
`
`factual matters set forth are true and correct.
`
`3.
`
`I am an attorney at law, licensed to practice in the State of New Jersey
`
`and the State of New York, and am an associate of the law firm Quinn Emanuel
`
`Urqhuart & Sullivan LLP, attorneys for Corcept Therapeutics, Inc. I make this
`
`Declaration in support of Patent Owner’s 37 C.F.R. § 42.64(b)(2) Response to
`
`Petitioner’s Objections to Evidence Submitted During the Preliminary Proceeding.
`
`4.
`
`I confirm that Exhibit 2010 is a true and correct printout of the
`
`webpage “Hyperglycemia in Diabetes - Symptoms and Causes - Mayo Clinic'
`
`that I downloaded on August 8, 2019 from the following web address:
`
`https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-
`
`causes/syc-20373631. I further confirm that an exhibit label has been added to this
`
`document but no other alterations have been made.
`
`5.
`
`I confirm that Exhibit 2045 is a true and correct printout of the
`
`webpage “Treatment for Aspergillosis - Centers for Disease Control and
`
`Prevention” that I downloaded on August 22, 2019 from the following web
`
`address: https://www.cdc.gov/fungal/diseases/aspergillosis/treatment.html. I
`
`1
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2048, Page 2
`
`
`
`further confirm that an exhibit label has been added to this document but no other
`
`alterations have been made.
`
`6.
`
`I confirm that Exhibit 2046 is a true and correct printout of the
`
`webpage “Drug Development and Drug Interactions: Table of Substrates,
`
`Inhibitors and Inducers” that I downloaded on August 22, 2019 from the following
`
`web address: https://www.fda.gov/drugs/drug-interactions-labeling/drug-
`
`development-and-drug-interactions-table-substrates-inhibitors-and-inducers. I
`
`further confirm that an exhibit label has been added to this document but no other
`
`alterations have been made.
`
`7.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further, that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by fine
`
`or imprisonment or both, under Section 1001 of Title 18 of the United States Code.
`
`8.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct.
`
`Date: 12.//^/^^/^
`
`Nicholas A. LoCastro
`
`2
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2048, Page 3
`
`